.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
The ADAURA trial provided phase 3 evidence for adjuvant osimertinib after complete resection of EGFR-mutated non-small-cell lung cancer. Patients with stage IB to IIIA disease were randomized to osimertinib or placebo for up to three years. The original analysis demonstrated a substantial disease-free survival advantage, and later follow-up confirmed an overall-survival benefit, including in the broader stage IB-IIIA population. This is important for the NAPCON lung-cancer track because it shows how biomarker testing can influence management even after apparently definitive surgery. The key clinical concept is that resection does not necessarily end the treatment pathway: molecular risk stratification can identify patients who may benefit from adjuvant targeted therapy. The study also illustrates why pathologic diagnosis, staging and molecular testing need to be integrated early enough to inform postoperative decisions. For practicing HCPs, the article is useful when discussing multidisciplinary tumor-board pathways and access to biomarker-driven therapy outside major metro centers. As with all targeted treatments, applicability depends on the presence of the relevant EGFR mutation and the clinical setting studied in the trial.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
The ADAURA trial provided phase 3 evidence for adjuvant osimertinib after complete resection of EGFR-mutated non-small-cell lung cancer. Patients with stage IB to IIIA disease were randomized to osimertinib or placebo for up to three years. The original analysis demonstrated a substantial disease-free survival advantage, and later follow-up confirmed an overall-survival benefit, including in the broader stage IB-IIIA population. This is important for the NAPCON lung-cancer track because it shows how biomarker testing can influence management even after apparently definitive surgery. The key clinical concept is that resection does not necessarily end the treatment pathway: molecular risk stratification can identify patients who may benefit from adjuvant targeted therapy. The study also illustrates why pathologic diagnosis, staging and molecular testing need to be integrated early enough to inform postoperative decisions. For practicing HCPs, the article is useful when discussing multidisciplinary tumor-board pathways and access to biomarker-driven therapy outside major metro centers. As with all targeted treatments, applicability depends on the presence of the relevant EGFR mutation and the clinical setting studied in the trial.
Today
The phase 3 ACACIA-HCM trial reveals that aficamten improves cardiac structure, diastolic relaxation, functional capacity, and symptom burden in symptomatic nonobstructive hypertrophic cardiomyopathy, marking a major milestone in targeted myosin inhibition.
6 days back
A clinical study shows that automated breast ultrasound paired with artificial intelligence accurately classifies BIRADS 3-4 lesions, reaching 95% sensitivity and 79% specificity. This diagnostic advance promises to reduce unnecessary core needle biopsies and refine clinical workflows in breast imaging.
3 weeks back
Researchers have engineered freestanding hierarchical-porous BCZT thin films that resist cracking and enhance ultrasonic energy harvesting in soft tissue. Achieving high piezoelectric output and acoustic matching, this lead-free material offers transformative potential for implantable bioelectronics.
6 days back
A novel pathology-adaptive surface engineering strategy uses functionalized plasma polymer coatings to selectively modulate AGE adsorption, reducing oxidative stress and restoring bone formation in diabetic and aging microenvironments.
3 weeks back
A breakthrough study identifies the Klotho/PKCα/CUX1/SPARC/TGFβ-RII axis as a critical driver of podocyte mitochondrial injury and ferroptosis in diabetic kidney disease, unveiling promising molecular targets to halt renal disease progression.
6 days back
